Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2017 1
2020 1
2021 28
2022 86
2023 71
2024 60
2025 74
2026 67

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

328 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for clopidogrel at thrombosis stents "last 5 years"[dp]
Your search for Clopidogrel DVT thrombosis stents "last 5 years"[dp] retrieved no results
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.
Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, Suwa S, Isawa T, Domei T, Yamaji K, Tatsushima S, Watanabe H, Ohya M, Tokuyama H, Tada T, Sakamoto H, Mori H, Suzuki H, Nishikura T, Wakabayashi K, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Morino Y, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 ACS Investigators. Watanabe H, et al. JAMA Cardiol. 2022 Apr 1;7(4):407-417. doi: 10.1001/jamacardio.2021.5244. JAMA Cardiol. 2022. PMID: 35234821 Free PMC article. Clinical Trial.
INTERVENTIONS: Patients were randomized either to 1 to 2 months of DAPT followed by clopidogrel monotherapy (n = 2078) or to 12 months of DAPT with aspirin and clopidogrel (n = 2091). MAIN OUTCOMES AND MEASURES: The primary end point was a composite of cardiovascula …
INTERVENTIONS: Patients were randomized either to 1 to 2 months of DAPT followed by clopidogrel monotherapy (n = 2078) or to 12 month …
Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention.
Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Nishikawa R, Ando K, Ono K, Kadota K, Suwa S, Morishima I, Yoshida R, Hata Y, Akao M, Yagi M, Suematsu N, Morino Y, Yokomatsu T, Takamisawa I, Noda T, Doi M, Okayama H, Nakamura Y, Hibi K, Sakamoto H, Noguchi T, Kimura T; STOPDAPT-2 Investigators. Watanabe H, et al. J Am Coll Cardiol. 2024 Jan 2;83(1):17-31. doi: 10.1016/j.jacc.2023.10.013. Epub 2023 Oct 23. J Am Coll Cardiol. 2024. PMID: 37879491 Free article. Clinical Trial.
OBJECTIVES: This study compared clopidogrel monotherapy following 1 month of DAPT (clopidogrel group) with aspirin monotherapy following 12 months of DAPT (aspirin group) after PCI for 5 years. ...Patients who underwent PCI with cobalt-chromium everolimus-eluting …
OBJECTIVES: This study compared clopidogrel monotherapy following 1 month of DAPT (clopidogrel group) with aspirin monotherapy …
Dual Antiplatelet Therapy: A Concise Review for Clinicians.
Virk HUH, Escobar J, Rodriguez M, Bates ER, Khalid U, Jneid H, Birnbaum Y, Levine GN, Smith SC Jr, Krittanawong C. Virk HUH, et al. Life (Basel). 2023 Jul 18;13(7):1580. doi: 10.3390/life13071580. Life (Basel). 2023. PMID: 37511955 Free PMC article. Review.
Prolonged DAPT beyond 12 months reduces stent thrombosis, major adverse cardiovascular events, and myocardial infarction rates but increases bleeding risk. ...Carotid artery disease patients with transient ischemic attack or stroke benefit from antiplatelet therapy …
Prolonged DAPT beyond 12 months reduces stent thrombosis, major adverse cardiovascular events, and myocardial infarction rates …
Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial.
Watanabe H, Natsuaki M, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R, Kimura T, Ando K, Domei T, Suwa S, Ogita M, Isawa T, Takenaka H, Yamamoto T, Ishikawa T, Hisauchi I, Wakabayashi K, Onishi Y, Hibi K, Kawai K, Yoshida R, Suzuki H, Nakazawa G, Kusuyama T, Morishima I, Ono K, Kimura T. Watanabe H, et al. Eur Heart J. 2024 Dec 16;45(47):5042-5054. doi: 10.1093/eurheartj/ehae617. Eur Heart J. 2024. PMID: 39215959 Free article. Clinical Trial.
This secondary analysis compared aspirin monotherapy with clopidogrel monotherapy by the 30-day landmark analysis. The co-primary endpoints were the cardiovascular endpoint defined as a composite of cardiovascular death, myocardial infarction, definite stent thro …
This secondary analysis compared aspirin monotherapy with clopidogrel monotherapy by the 30-day landmark analysis. The co-primary end …
Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome.
Valgimigli M, Landi A, Angiolillo DJ, Baber U, Bhatt DL, Bonaca MP, Capodanno D, Cohen DJ, Gibson CM, James S, Kimura T, Lopes RD, Mehta SR, Montalescot G, Sibbing D, Steg PG, Stone GW, Storey RF, Vranckx P, Windecker S, Mehran R. Valgimigli M, et al. Circulation. 2024 Jul 23;150(4):317-335. doi: 10.1161/CIRCULATIONAHA.124.069012. Epub 2024 Jul 22. Circulation. 2024. PMID: 39038086 Review.
Twelve-month DAPT was initially grounded in the results of the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) trial, which, by design, studied DAPT versus no DAPT rather than the optimal DAPT duration. ...Subsequent ACS studies, which were not designed t …
Twelve-month DAPT was initially grounded in the results of the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) tria …
Prasugrel Therapy and CYP Genotype.
Dean L, Kane M. Dean L, et al. 2017 Apr 10 [updated 2024 Oct 15]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. 2017 Apr 10 [updated 2024 Oct 15]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. PMID: 28520385 Free Books & Documents. Review.
Prasugrel is prescribed to reduce thrombotic cardiovascular events, such as stent thrombosis, myocardial infarction, and stroke in these individuals. Along with other antiplatelet agents such as clopidogrel and ticagrelor, prasugrel inhibits platelet activati …
Prasugrel is prescribed to reduce thrombotic cardiovascular events, such as stent thrombosis, myocardial infarction, and strok …
Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.
Lee SJ, Yu HT, Lee YJ, Lee SH, Heo JH, Ahn SG, Shin S, Doh JH, Her AY, Cho BR, Kim GS, Kwon TG, Lim SW, Shim J, Jang JY, Lee K, Cho YH, Choi CU, Lee SR, Park HB, Lee HC, Kim S, Yun KH, Ahn JH, Lee BK, Cho DK, Kim SY, Kim U, Kang TS, Choi SH, Kim WH, Lee JB, Rhee MY, Kim JB, Jo SH, Hyun DW, Kim D, Kim TH, Hong SJ, Uhm JS, Shin DH, Ahn CM, Kim BK, Joung B, Ko YG, Choi D, Hong MK, Jang Y, Pak HN, Kim JS; ADAPT AF-DES Investigators. Lee SJ, et al. N Engl J Med. 2026 Feb 12;394(7):658-668. doi: 10.1056/NEJMoa2512091. Epub 2025 Nov 8. N Engl J Med. 2026. PMID: 41211917 Clinical Trial.
BACKGROUND: Despite guideline recommendations, evidence for the use of non-vitamin K antagonist oral anticoagulant (NOAC) monotherapy in patients with atrial fibrillation after implantation of a drug-eluting stent remains limited. METHODS: In this multicenter, randomized, …
BACKGROUND: Despite guideline recommendations, evidence for the use of non-vitamin K antagonist oral anticoagulant (NOAC) monotherapy in pat …
Efficacy and Safety of Prasugrel, Ticagrelor, or Clopidogrel After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.
Maqsood MH, Feit F, Kaul U, Rao SV, Giacoppo D, Kastrati A, Bangalore S. Maqsood MH, et al. JAMA Cardiol. 2026 Jul 1;11(7):651-658. doi: 10.1001/jamacardio.2026.1128. JAMA Cardiol. 2026. PMID: 42201709
Compared with clopidogrel, there was a lower risk of MACE (OR, 0.80; 95% CI, 0.69-0.93) driven by lower myocardial infarction (OR, 0.71; 95% CI, 0.62-0.82) and stent thrombosis (OR, 0.48; 95% CI, 0.37-0.62) with prasugrel. MACE was not reduced with ticagrelor …
Compared with clopidogrel, there was a lower risk of MACE (OR, 0.80; 95% CI, 0.69-0.93) driven by lower myocardial infarction (OR, 0. …
Aspirin Versus Clopidogrel Beyond 1 Month After PCI in Patients With Oral Anticoagulation.
Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R, Kimura T, Ando K, Suwa S, Isawa T, Takenaka H, Ishikawa T, Tamura T, Kawahatsu K, Hayashi F, Akao M, Serikawa T, Mori H, Kawamura T, Hagikura A, Shibata N, Ono K, Kimura T. Natsuaki M, et al. Circ Cardiovasc Interv. 2025 Nov;18(11):e015495. doi: 10.1161/CIRCINTERVENTIONS.125.015495. Epub 2025 Sep 24. Circ Cardiovasc Interv. 2025. PMID: 40988628 Free article. Clinical Trial.
BACKGROUND: There were no previous studies comparing aspirin with clopidogrel on top of oral anticoagulation (OAC) within 1 year after percutaneous coronary intervention when dual therapy with OAC and clopidogrel was recommended. ...The coprimary end points were the …
BACKGROUND: There were no previous studies comparing aspirin with clopidogrel on top of oral anticoagulation (OAC) within 1 year afte …
Aging and Antithrombotic Treatment.
Valeriani E, Bartimoccia S, Pignatelli P, Pastori D. Valeriani E, et al. Antioxid Redox Signal. 2024 Sep;41(7-9):542-556. doi: 10.1089/ars.2023.0373. Epub 2023 Oct 25. Antioxid Redox Signal. 2024. PMID: 37742116 Review.
In elderly patients with acute coronary syndrome, low-dose prasugrel or clopidogrel, shorter dual antiplatelet therapy, and no pretreatment before stent placement should be considered. ...
In elderly patients with acute coronary syndrome, low-dose prasugrel or clopidogrel, shorter dual antiplatelet therapy, and no pretre …
328 results